GB600

GB600 is an investigational small molecule drug candidate being developed by Galleon Bio for the treatment of diabetic neuropathy. It is part of a pipeline of strontium-based therapies that utilize the strontium ion (Sr2+) to address chronic pain and inflammatory conditions. While specific chemical details for GB600 are limited, the Galleon Bio platform focuses on the therapeutic potential of strontium as a modulator of the calcium-sensing receptor (CaSR) and an inhibitor of transient receptor potential (TRP) channels, such as TRPV1, which are involved in the transmission of neuropathic pain. GB600 represents a targeted application of this strontium technology specifically for the management of pain associated with diabetic nerve damage.